carbonic acid bis-(2-phenyl-ethyl)ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carbonic acid bis-(2-phenyl-ethyl)ester
• 英文别名: phenyl-ethylcarbonate；2-Phenylethyl hydrogen carbonate
• 化学式: C₉H₁₀O₃
• 分子量: 166.177
• InChiKey: RYLBXVJICCIUQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  carbonic acid bis-(2-phenyl-ethyl)ester 、 1-壬醇 、 苯酚 在 Ti(Oφ)4 作用下， 以 正庚烷 为溶剂， 生成 碳酸二苯酯
  参考文献：
  名称：

  Process for the preparation of aromatic carbonates

  摘要：

  一种具有以下结构式的芳香碳酸酯：##STR1##其中R'是烷基，R是烷基、烷氧基、芳基、芳氧基或NO.sub.2，通过在AlCl.sub.3等催化剂存在下将相关酚或其酰基酯与烷基、环状或芳基烷基碳酸酯反应制备而成。

  公开号：

  US04182726A1
• 作为产物：
  描述：

  乙基环己烷 、 乙基苯基碳酸脂 生成 carbonic acid bis-(2-phenyl-ethyl)ester
  参考文献：
  名称：

  Process for the preparation of aromatic carbonates

  摘要：

  该发明涉及一种从苯基烷基碳酸酯开始制备二芳基碳酸酯的过程，反应在适当催化剂的存在下进行，该催化剂能够提供更高的产率和选择性；催化系统被选择在Lewis酸或过渡金属化合物之间。

  公开号：

  US04045464A1

文献信息

• Certain azacycloalkyl substituted acetic acid derivatives
  申请人：——

  公开号：US20040235896A1

  公开（公告）日：2004-11-25

  Compounds of the formula (I) wherein R represents OH or NHOH; R 1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R 2 represents biarylsulfonyl or aryloxyarylsufonyl; R 3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R 4 and R 5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals. 1

  式(I)化合物，其中R代表OH或NHOH；R1代表氢、可选择性取代的低级烷基、芳基-低级烷基、环烷基-低级烷基或源自羧酸、碳酸、氨基甲酸或磺酸的酰基；R2代表双芳基磺酰基或芳氧基芳基磺酰基；R3代表氢、可选择性取代的低级烷基、芳基-低级烷基、环烷基-低级烷基或源自羧酸、碳酸或氨基甲酸的酰基；R4和R5各自独立地代表氢、低级烷基、低级烷氧羰基、芳基-低级烷基或环烷基-低级烷基；m为0、1、2或3；其药学上可接受的药物前体衍生物；其药学上可接受的盐；包含所述化合物的药物组合物；以及它们用于抑制基质降解金属蛋白酶和预防或治疗哺乳动物中依赖基质金属蛋白酶的状况的用途。
• Penem derivatives and antimicrobial agents containing the same
  申请人：SUNTORY LIMITED

  公开号：EP0774465A1

  公开（公告）日：1997-05-21

  Penem derivatives represented by the following Formula (I): wherein Z represents a hydroxyl group or a fluorine atom, R1 represents a substituted or unsubstituted alkyl, alkenyl, aralkyl group, aryl group, heterocyclic, or acyl group, or a hydrogen atom, and R2 represents a hydrogen atom or a carboxyl-protecting group; and pharmacologically acceptable salts thereof are antibacterial agents effective against, inter alia, methicillin-resistant Staphylococcus aureus. The derivatives and salts are novel except when R1 is ethyl and Z is hydroxyl. The analogous compounds in which R2 is a carboxyl-protecting group and any hydroxyl group represented by Z is protected are novel process intermediates.

  Penem衍生物由以下公式（I）表示：其中Z代表一个羟基团或氟原子，R1代表一个取代或未取代的烷基，烯基，芳基甲基，芳基，杂环基或酰基，或氢原子，R2代表一个氢原子或羧基保护基；及其药理学上可接受的盐是有效的抗菌剂，可用于治疗耐甲氧西林金黄色葡萄球菌等感染。这些衍生物和盐是新颖的，除非R1是乙基且Z是羟基。其中R2是羧基保护基且Z代表的任何羟基被保护的类似化合物是新颖的工艺中间体。
• TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS
  申请人：Goossens Thomas Peter Anne

  公开号：US20130090492A1

  公开（公告）日：2013-04-11

  This invention is directed to a general catalyst of high activity and selectivity for the production of a variety of esters, particularly acrylate and methacrylate-based esters, by a transesterification reaction. This objective is achieved by reaction of an ester of a carboxylic or a carbonic acid, in particular of a saturated or unsaturated, typically, a 3 to 4 carbon atom carboxylic acid; with an alcohol in the presence of a catalyst comprising the combination of a metal 1,3-dicarbonyl complex (pref. Zn or Fe acetylacetonate) and a salt, in particular an inorganic salt, pref. ZnCl2, LiCI, NaCI, NH4CI or Lil. These catalysts are prepared from readily available starting materials within the reaction medium without the need for isolation (in-situ preparation).

  这项发明针对一种高活性和选择性的通用催化剂，用于通过酯交换反应生产各种酯类，特别是丙烯酸酯和甲基丙烯酸酯。该目标通过在存在催化剂的情况下，将羧酸酯或碳酸酯的酯，特别是饱和或不饱和的、通常为3到4个碳原子的羧酸酯；与醇反应来实现。催化剂包括金属1,3-二羰基配合物（首选Zn或Fe乙酰丙酮酸盐）和盐的组合，特别是无机盐，首选ZnCl2，LiCl，NaCl，NH4Cl或I2。这些催化剂是在反应介质中从易得的起始物质制备而成，无需分离（原位制备）。
• [EN] SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS<br/>[FR] PROCÉDÉ DE SYNTHÈSE POUR LA PRÉPARATION DE COMPOSÉS ECTEINASCIDINES
  申请人：PHARMA MAR SA

  公开号：WO2011147828A1

  公开（公告）日：2011-12-01

  This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ectainascidins of formula I from compounds of formula II, and to processes for the synthesis of compounds of formula II.

  这项发明涉及到式子II的化合物：其中R1、R2、ProtSH和ProtNH的定义如下，以及从式子II的化合物合成式子I的ectainascidins的过程，以及合成式子II的化合物的过程。
• PHARMACEUTICAL AGENT
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2018855A1

  公开（公告）日：2009-01-28

  The present invention provides an agent for the prophylaxis or treatment of complications after coronary-artery bypass surgery or cardiac diseases, autoimmune diseases, central nervous system diseases, inflammatory diseases, sepsis, severe sepsis or septic shock in a patient who undergoes coronary-artery bypass surgery, which comprises a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof, and an agent for the prophylaxis or treatment of sepsis and the like, as well as complications after coronary-artery bypass surgery, which is prepared for administration of ethyl (6R)-6-[(2-chloro-4-fluoroanilino)sulfonyl]-1-cyclohexene-1-carboxylate or a salt thereof or a prodrug thereof in a specific dose at a specific administration time.

  本发明提供了一种用于预防或治疗冠状动脉旁路手术或心脏疾病、自身免疫疾病、中枢神经系统疾病、炎症性疾病、败血症、重型败血症或脓毒性休克后并发症的药剂，该药剂包括由式(I)表示的化合物：其中每个符号如规范中定义，或由式(II)表示的化合物：其中每个符号如规范中定义，或其盐或前药，以及一种用于预防或治疗败血症等并发症及冠状动脉旁路手术后并发症的药剂，该药剂用于在特定剂量和特定给药时间内给予乙酸乙酯(6R)-6-[(2-氯-4-氟苯胺基)磺酰]-1-环己烯-1-羧酸乙酯或其盐或前药。